SCHEMBL3769477

SCHEMBL3769477

[C]#Cc1c[nH]c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 2/20 0.64
IMPDH1 P20839 1/20 0.64
ATM Q13315 2/20 0.48
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
CYP3A4 P08684 3/20 0.47
GPR84 Q9NQS5 3/20 0.47
MAPT P10636 2/20 0.47
AHR P35869 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CYP2D6 P10635 2/20 0.44
PRKD3 O94806 1/20 0.44
CCNB2 O95067 1/20 0.44
CCNE2 O96020 1/20 0.44
ABL1 P00519 1/20 0.44
PRKCG P05129 1/20 0.44
PRKCB P05771 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17506602 0.82 IMPDH2 (0.69) IMPDH2IMPDH1ATMMEN1KMT2A
SCHEMBL5130557 0.78 IMPDH2 (0.64) IMPDH2IMPDH1ATMMEN1KMT2A
SCHEMBL30277938 0.78 IMPDH2 (0.64) IMPDH2IMPDH1ATMMEN1KMT2A
SCHEMBL96479 0.78 IMPDH2 (0.64) IMPDH2IMPDH1ATMMEN1KMT2A
SCHEMBL29820843 0.78 IMPDH2 (1.00) IMPDH2IMPDH1ATMMEN1KMT2A
SCHEMBL1752696 0.78 IMPDH2 (0.64) IMPDH2IMPDH1ATMMEN1KMT2A
SCHEMBL4736533 0.78 IMPDH2 (0.64) IMPDH2IMPDH1ATMMEN1KMT2A
SCHEMBL7237886 0.78 IMPDH2 (0.64) IMPDH2IMPDH1ATMMEN1KMT2A
SCHEMBL186741 0.78 IMPDH2 (1.00) IMPDH2IMPDH1ATMMEN1KMT2A
Hydrochloric Acid SCHEMBL7431978 0.77 IMPDH2 (0.96) IMPDH2IMPDH1ATMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA IMPDH2 1378/4885IMPDH1 1332/4885ATM 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.